Editas Medicine shares fall 1.75% intraday after announcing EDIT-401 as lead in vivo development candidate.

Editas Medicine, Inc. declined 1.75% in intraday trading. The company recently announced the nomination of EDIT-401 as its lead in vivo development candidate, highlighting its differentiated upregulation-only strategy and proprietary gene editing platform based on CRISPR technology. The company also held a webinar to discuss the strategic overview and key milestones for EDIT-401, showcasing its commitment to developing transformative genomic medicines.